

	1	2	3	4	5	6	7	8	9	10
--	---	---	---	---	---	---	---	---	---	----

Clinical parameters										
Peak O ₂ requirements	RA	RA	2L NP	RA	RA	RA	RA	RA	RA	3L NP
Day of deterioration ^g	NA	NA	D 13 illness	NA	NA	NA	NA	NA	NA	D 17 illness
Peak O ₂ requirements	RA	RA	2L NP	RA	RA	RA	RA	RA	RA	3L NP

COVID-19 management										
COVID-19-specific treatment (no. of days)	Sotrovimab Rem (5)	Sotrovimab	Sotrovimab Rem (5) Dexa (5)	Sotrovimab Rem (10)	- Rem (5)	Nil	Sotrovimab Rem (3)	Sotrovimab Rem (3)	- Rem (3 days, followed by another 5 days from D 11 illness)	Rem (3) Dexa (3)
Adjustment of IS	Nil	Nil	MMF stopped	MMF dose reduced	Aza stopped	Nil	MPA stopped	MMF stopped	Nil	Aza stopped

Final disposition										
C+ severity at discharge	Moderate	Asymptomatic	Severe	Moderate	Moderate	Mild	Mild	Moderate	Moderate	Severe
Outcome	Recovered	Recovered	Recovered	Recovered	Recovered	Recovered	Recovered	Recovered	Recovered	Recovered

ABO: ABO incompatible; abs: absolute; ATG: anti-thymocyte globulin; Aza: azathioprine; BAS: basiliximab, C+: COVID-19 infection; CsA: ciclosporin; CT: cycle threshold; DDRT: deceased donor renal transplant; Dexa: dexamethasone; DM: diabetic; EVR: everolimus; FK: tacrolimus; GN: glomerulonephritis; HTN: hypertensive; ICU: intensive care unit; IS: immunosuppression; LDRT: living donor renal transplant; Lf: lymphocyte; MMF: mycophenolate mofetil; MP: methylprednisolone; MPA: mycophenolic acid EC; NA: not available; NP: nasal prongs; Pred: prednisolone; RA: room air; RBD: receptor binding domain; Rem: remdesivir; Sx: symptoms; TIRF: type 1 respiratory failure; Tx: transplant; ; URTI: upper respiratory tract infection; ;

^a This was a transplant performed at an overseas transplant centre and we did not have information with regard to the induction immunosuppression used.

^b Serological testing against COVID-19 was performed at the point of admission to our hospital, prior to the receipt of any COVID-19 specific therapeutics.

^c D1 of illness is defined as the onset of clinical symptoms OR the day of first positive COVID-19 test (either by polymerase chain reaction [PCR] or antigen testing), whichever is earlier.

^d Severity of disease is based on the classification by the National Institutes of Health. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at: <https://www.covid19treatmentguidelines.nih.gov/>. Accessed on 17 October 2021.

^e This refers to radiological evidence of pneumonia as characterised by chest infiltrates.

^f Duration of viral shedding is defined as the time taken for the SARS-COV-2 PCR CT to reach >30.

^g The day of clinical deterioration is in relation to onset of clinical illness OR the first positive COVID-19 test (either by PCR or antigen testing).